Consainsights logo

Anti Viral Therapeutics Market Size, Share, Industry Trends and Forecast to 2030

Anti Viral Therapeutics Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.


  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

1. Market Size & CAGR of Anti Viral Therapeutics Market in 2021

The global anti-viral therapeutics market recorded a market size of USD 51.2 billion in 2021. The market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2021 to 2028. By 2028, the market size is expected to reach USD 76.4 billion. The increasing prevalence of viral infections, advancements in drug development, and growing investments in healthcare infrastructure are driving the growth of the anti-viral therapeutics market.

2. COVID-19 Impact on the Anti Viral Therapeutics Market

The COVID-19 pandemic has had a significant impact on the anti-viral therapeutics market. The demand for anti-viral drugs surged following the outbreak of the virus in December 2019. Pharmaceutical companies focused on developing new anti-viral treatments and vaccines to combat the spread of the virus. The pandemic also led to increased research and development activities in the field of anti-viral therapeutics.

3. Anti Viral Therapeutics Dynamics

The anti-viral therapeutics market is driven by factors such as the increasing prevalence of viral infections, advancements in drug development, and growing awareness about the importance of antiviral treatments. Additionally, the rise in healthcare spending, technological advancements in drug delivery systems, and the emergence of new viruses are contributing to the growth of the market. However, challenges such as the high cost of antiviral drugs, stringent regulatory requirements, and the emergence of drug-resistant viruses are hindering market growth.

4. Segments and Related Analysis

4.1 Drug Type Segmentation

The anti-viral therapeutics market is segmented based on drug types, including nucleoside analogues, protease inhibitors, reverse transcriptase inhibitors, and others. Nucleoside analogues accounted for the largest market share in 2021, attributed to their widespread use in treating viral infections such as HIV and hepatitis.

4.2 Application Segmentation

The market is further segmented based on applications, including HIV/AIDS, hepatitis, influenza, herpes, and others. The HIV/AIDS segment dominated the market in 2021, driven by the high prevalence of HIV infections globally and the availability of effective antiretroviral therapies.

5. By Region Analysis

5.1 North America

North America accounted for the largest market share in the anti-viral therapeutics market in 2021, attributed to the presence of key market players, high healthcare expenditure, and advanced healthcare infrastructure. The region is expected to continue its dominance during the forecast period.

5.2 Europe

Europe is a significant region in the anti-viral therapeutics market, driven by the increasing prevalence of viral infections, rising investments in research and development activities, and the presence of leading pharmaceutical companies. The region is projected to witness substantial growth in the coming years.

6. Key Market Players and Competitive Landscape

Key players in the anti-viral therapeutics market include Gilead Sciences, AbbVie Inc., GlaxoSmithKline plc, Merck & Co., Inc., and Johnson & Johnson. These companies focus on strategic collaborations, product launches, and acquisitions to strengthen their market position and expand their product portfolio. The competitive landscape of the market is highly competitive, with companies vying for market share through innovation and research.

7. Recent Happenings in the Anti Viral Therapeutics Market

In recent years, there have been significant developments in the anti-viral therapeutics market. For example, Gilead Sciences launched a new antiviral drug for the treatment of COVID-19, which received emergency use authorization from regulatory authorities. Additionally, AbbVie Inc. announced the acquisition of a biopharmaceutical company specializing in antiviral therapies, expanding its product portfolio in the market.

Frequently Asked Questions (FAQ):